Eli Lilly and Company, Indianapolis, Indiana, USA.
Tech Data Service, King of Prussia, Pennsylvania, USA.
Diabetes Obes Metab. 2023 Dec;25(12):3748-3756. doi: 10.1111/dom.15269. Epub 2023 Sep 12.
We assessed the impact of tirzepatide on 10-year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT-1 trial.
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo. Mean changes in risk scores from baseline to weeks 24 and 72 were compared between tirzepatide and placebo groups. Subgroup analyses were conducted based on participants' glycaemic status and body mass index at baseline.
Mean baseline T2D predicted risk scores did not differ between tirzepatide and placebo groups (range: 22.9%-24.3%). At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%). At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%. For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo. At week 72, participants with prediabetes (range: 16.0%-20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%-11.3%). Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo.
Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.
我们评估了替西帕肽对 SURMOUNT-1 试验参与者发生 2 型糖尿病（T2D）的 10 年预测风险的影响。
在 SURMOUNT-1 的这项事后分析中，使用心血管疾病分期风险引擎来计算基线、第 24 周和第 72 周接受 5、10 或 15mg 替西帕肽或安慰剂治疗的参与者发生 T2D 的 10 年预测风险。比较替西帕肽组和安慰剂组之间从基线到第 24 周和第 72 周风险评分的平均变化。根据参与者基线时的血糖状态和体重指数进行亚组分析。
替西帕肽组和安慰剂组的基线 T2D 预测风险评分无差异（范围：22.9%-24.3%）。在第 72 周，替西帕肽组的 T2D 预测风险评分绝对降低幅度明显大于安慰剂组（5mg，12.4%；10mg，14.4%；15mg，14.7%）（0.7%）。在第 72 周，替西帕肽治疗后预测风险的中位数相对降低范围为 60.3%至 69.0%。对于有和没有糖尿病前期的参与者，替西帕肽组的风险降低幅度明显大于安慰剂组。在第 72 周，有糖尿病前期（范围：16.0%-20.3%）的参与者的风险评分从基线的降低幅度大于无糖尿病前期（范围：10.1%-11.3%）的参与者。在所有体重指数亚组中，替西帕肽组从基线的平均降低幅度明显大于安慰剂组。
无论基线血糖状态如何，与安慰剂相比，替西帕肽治疗可显著降低肥胖或超重参与者发生 T2D 的 10 年预测风险。
